Floatz logo

32 assets in Peritoneal Carcinomatosis

Therapeutic assets addressing Peritoneal Carcinomatosis, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Fluorouracilum
Peritoneal Carcinomatosis
Ciusss de L'Est de l'Île de MontréalP3BB (68)
Cis-Diamminedichloroplatinum Ii
Peritoneal Carcinomatosis
National Cancer Institute (NCI)P3BB (66)
Irinotecan
Peritoneal Carcinomatosis
Catharina Ziekenhuis EindhovenP3BB (66)
Muamycin
Peritoneal Carcinomatosis
H. Lee Moffitt Cancer Center and Research InstituteP4BB (66)
Oxaliplatin
Peritoneal Carcinomatosis
Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityP3BB (66)
Capecitabine
Peritoneal Carcinomatosis
Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityP2/3BB (65)
Sodium Thiosulfate
Peritoneal Carcinomatosis
National Cancer Institute (NCI)P2B (61)
Radspherin
Peritoneal Carcinomatosis
Oncoinvent Solutions ASP2B (58)
Nilotinib
Peritoneal Carcinomatosis
National Cancer Institute (NCI)P2B (57)
Adriamycin
Peritoneal Carcinomatosis
National Cancer Institute (NCI)P1/2CCC (53)
Lubiprostone
Peritoneal Carcinomatosis
Sun Yat-sen UniversityP2CCC (53)
Nivolumab
Peritoneal Carcinomatosis
Enlivex Therapeutics RDO Ltd.P1/2CCC (53)
Recombinant Mutant Human Tumor Necrosis Factor
Peritoneal Carcinomatosis
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityP2CCC (53)
Technetium [99Mtc]-H7Nd
Peritoneal Carcinomatosis
Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.P2CCC (53)
Tislelizumab
Peritoneal Carcinomatosis
Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityP1/2CCC (52)
Allocetra-Ots
Peritoneal Carcinomatosis
Enlivex Therapeutics RDO Ltd.P1/2CC (47)
Cetuximab
Peritoneal Carcinomatosis
M.D. Anderson Cancer CenterP1/2CC (47)
Cyclophosphamide
Peritoneal Carcinomatosis
M.D. Anderson Cancer CenterP1/2CC (47)
Fludarabine
Peritoneal Carcinomatosis
M.D. Anderson Cancer CenterP1/2CC (47)
Nadravaleucel
Peritoneal Carcinomatosis
M.D. Anderson Cancer CenterP1/2CC (47)
Galunisertib
Peritoneal Carcinomatosis
The Netherlands Cancer InstituteP1/2CC (45)
Cea-Targeted Car-T
Peritoneal Carcinomatosis
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityP1CC (43)
Certepetide
Peritoneal Carcinomatosis
University of California, San DiegoP1CC (43)
Raltitrexed
Peritoneal Carcinomatosis
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityP1CC (43)
vg2025
Peritoneal Carcinomatosis
M.D. Anderson Cancer CenterP1CC (43)
Imp-321
Peritoneal Carcinomatosis
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestP1CC (41)
m28z1xxpd1dnr car
Peritoneal Carcinomatosis
Memorial Sloan Kettering Cancer CenterP1CC (41)
Avelumab
Peritoneal Carcinomatosis
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestP1CC (40)
Adavosertib
Peritoneal Carcinomatosis
M.D. Anderson Cancer CenterEarly P1C (39)
Pd-L1 Car-T Cells
Peritoneal Carcinomatosis
Sichuan UniversityEarly P1C (39)
R130
Peritoneal Carcinomatosis
Shanghai Yunying Medical TechnologyEarly P1C (38)
gk02
Peritoneal Carcinomatosis
Beijing Geekgene Technology Co., LTDEarly P1NR ()